| Compound |
Fa(%) |
Fa types |
Literature references |
Remarks |
| Ganciclovir |
3 |
Low |
[176] |
|
| Melagatran |
5 |
Low |
In-house |
|
| Enalaprilat |
10 |
Low |
[177] |
|
| Sulphasalazine |
12 |
Low |
[178] |
Drain substrate |
| Acyclovir |
17 |
Low |
[128,180] |
|
| Chlorothiazide |
25 |
Middle |
[178,180] |
Dose-dependent F;saturated abs |
| Mannitol |
26 |
Middle |
[178,181] |
|
| Atenolol |
56 |
Middle |
[178,182] |
|
| Zomig |
60 |
Middle |
In-house |
|
| Ranitidine |
61 |
Middle |
[183] |
The Fa value is calculated from Fa=F/(1-CLH/QH); With transport protein interaction |
| Digoxin |
81 |
High |
[184] |
Static urinary excretion data, Fa values can be calculated from the oral and intravenous injection ;P-gp substrate |
| Methotrexate |
82 |
High |
[185] |
Static urinary excretion data, Fa values can be calculated from the oral and intravenous injection; a decrease in absorption at high doses |
| Quinidine |
90 |
High |
[186] |
The Fa value is calculated from Fa=F/(1-CLH/QH); P-gp/MRP inhibitor/substrate |
| Antipyrine |
100 |
High |
[187] |
|
| Caffeine |
100 |
High |
[188] |
|
| Metoprolol |
100 |
High |
[178,189] |
|
| probenecid |
100 |
High |
[190] |
MRP inhibitor/substrate |
| Propranolol |
100 |
High |
[191] |
|
| Testerone |
100 |
High |
[192] |
|
| Theophylline |
100 |
High |
[193] |
|
| Verapamil |
100 |
High |
[194] |
P-gp/MRP substrate inhibitor |
| D-glucose |
100 |
High |
|
Glucose transport protein |
| Glycine-proline |
100 |
High |
|
Dipeptide transport protein |
| L-leucine |
100 |
High |
|
Amino acid transport protein |
| L-phenylalanine |
100 |
High |
|
Amino acid transport protein |